Gene-edited peanuts hit harvest milestone in first U.S. field trial with 3 allergens removed

Gene-edited peanuts engineered to lack three of the proteins most closely tied to severe allergic reactions have reached harvest in Georgia, in what their developers describe as the first outdoor, commercial-scale planting of such a crop in the United States. Minneapolis-based food technology startup Nurtured Nuts planted the crop in spring 2026 using lines supplied by AgriNetica, the U.S. arm of Israeli agricultural biotechnology company BetterSeeds, Global Agriculture reported on Oct. 3, 2026.

The move from greenhouse to open field is the step that shows whether an edited trait holds up under commercial growing conditions. For growers, shellers and food manufacturers, the open questions are whether the edited lines yield, process and taste like conventional peanuts, and whether regulators will accept the product. None of those answers is public yet.

How the gene-edited peanuts were developed

AgriNetica used CRISPR to knock out the genes that produce three proteins, Ara h 2, Ara h 6 and Ara h 7. All three are 2S albumins, a group of small, water-soluble seed storage proteins, according to Fi Global Insights. The edit leaves Ara h 1 and Ara h 3 untouched, and those two proteins supply most of the protein in a peanut.

Nurtured Nuts founder Bryant Williams told Fi Global Insights that the edits are made at the seed stage and that the plant compensates for the proteins it no longer produces. AgriNetica is responsible for the scientific research and the clinical studies behind the product, according to Food Business News reporting cited by the Genetic Literacy Project.

The targets are well established in the scientific literature. Ara h 2 is recognized by IgE antibodies in more than 90% of peanut-allergic individuals, according to a review in Frontiers in Allergy. Earlier work using RNA interference reduced Ara h 2 in seeds by about 25%, the same review said. A later review of CRISPR work in peanuts reported that a 2024 study edited Ara h 2, Ara h 6 and Ara h 7 together without adversely affecting plant growth.

Timeline points to a 2027 launch pending FDA review

Harvest was scheduled to begin in September, with processing in October and a projected commercial launch in 2027 pending review by the U.S. Food and Drug Administration, the Genetic Literacy Project reported on Aug. 28, 2026. Global Agriculture reported on Oct. 3 that harvesting is under way.

The company calls the product “allergen-less” and does not claim that people with a peanut allergy can eat it today, Fi Global Insights reported. Studies are still under way. The stated aim is to lower the risk of accidental exposure in shared settings such as schools, hospitals and aircraft, where peanuts are often restricted. About six million Americans have a peanut allergy, according to the Genetic Literacy Project report.

Williams expects the trait to spread widely. “Ultimately, this will become the dominant form of peanut,” he said, according to the Genetic Literacy Project. Nurtured Nuts has not yet carried out sensory or functionality testing, although it expects the peanuts to taste and behave like conventional ones, Fi Global Insights reported.

What remains unproven

The evidence so far comes from the companies and from trade coverage. The reports reviewed cite no published yield, quality or allergenicity data from the Georgia crop, and the planting covers a single location and a single season. Removing three allergens also does not make a peanut allergen-free, because other allergenic proteins remain in the seed.

Commercial use would raise practical issues beyond the field. A low-allergen claim would depend on keeping gene-edited peanuts separate from conventional lots through shelling, storage and processing, which adds cost to a supply chain built for bulk handling. Seed access is a further question. Patent rights and labeling remain contested in gene-edited crops, as the debate over precision breeding in the U.K. has shown.

The next markers are the processing results from the 2026 crop, the outcome of the clinical work led by AgriNetica and the timing of the FDA review. Those will determine whether gene-edited peanuts move from a single Georgia planting to contracted acreage in 2027.

Sources: Global Agriculture, Fi Global Insights, Genetic Literacy Project